Hematopoietic and Lymphoid Cell Neoplasm Clinical Trial
Official title:
A Randomized Pilot Study of Human Lysozyme Goat Milk in Recipients of Standard Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
This randomized pilot phase I trial studies the side effects of human lysozyme goat milk in treating patients with blood cancer undergoing a donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving human lysozyme goat milk to patients undergoing a donor stem cell transplant may stop this from happening.
PRIMARY OBJECTIVES:
I. To evaluate the safety and feasibility of human lysozyme goat milk (hLZ) treatment by
assessing type, frequency, severity, attribution, time course and duration of adverse events,
including diarrhea, bloodstream/intestinal infections.
II. To evaluate the safety and feasibility of hLZ treatment by assessing patient compliance,
the patients' ability to drink the specified volume (250 ml 3 x/day) of hLZ during the
treatment period.
SECONDARY OBJECTIVES:
I. To compare the incidence and severity of adverse events (AE) among hLZ-treated and
untreated patients, including diarrhea, bloodstream infections and intestinal infections.
II. To obtain preliminary estimates of gut microbiome diversity, as assessed by the Simpson
Index, in hLZ-treated/untreated patients.
III. To compare gut microbiome diversity among hLZ-treated/untreated patients. IV. To obtain
a preliminary estimate of the possible association between gut microbiome diversity and
bloodstream infections.
V. To obtain a preliminary estimate of the possible association between gut microbiome
diversity and acute graft versus host disease (GVHD) cumulative incidence, including time to
onset.
VI. To characterize and compare GVHD inflammatory biomarkers (presence, level) among
hLZ-treated and untreated patients.
VII. To characterize and compare urinary uindoxyl sulfate, tryptophan and kynurenine levels
between hLZ-treated and untreated patients.
IX. To estimate overall survival (OS) cumulative incidence (CI) chronic GVHD of
relapse/progression, and non-relapse mortality (NRM) at 100 days (excluding chronic GVHD), 6
months, 1 year and 2 years.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I:
CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo
fractionated total body irradiation (FTBI) on days -7 to -4, and receive cyclophosphamide on
days -3 to -2 or etoposide on day -3 per City of Hope (COH) standard operating procedure
(SOP) in the absence of disease progression or unacceptable toxicity.
HLZ: Patients receive human lysozyme goat milk orally (PO) three times daily (TID) on days -8
to 28 in the absence of disease progression or unacceptable toxicity.
TRANSPLANT: Patients undergo stem cell infusion on day 0.
GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per
COH SOP in the absence of disease progression or unacceptable toxicity.
ARM II:
CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP,
undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on
day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.
TRANSPLANT: Patients undergo stem cell infusion on day 0.
GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per
COH SOP in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for up to 2 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT05106374 -
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
|
||
Recruiting |
NCT05660421 -
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
|
Phase 2 | |
Suspended |
NCT04060849 -
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
|
Phase 1 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Withdrawn |
NCT04127721 -
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT03712878 -
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT06062901 -
An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors
|
N/A | |
Terminated |
NCT04081298 -
eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors
|
N/A | |
Completed |
NCT04983901 -
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
|
Phase 2 | |
Recruiting |
NCT04188912 -
Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
|
||
Active, not recruiting |
NCT04592250 -
Financial Toxicity in Cancer Patients
|
||
Recruiting |
NCT05112614 -
Role of Gut Microbiome in Cancer Therapy
|
||
Active, not recruiting |
NCT04296305 -
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
|
Phase 4 | |
Withdrawn |
NCT04190433 -
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
|
Phase 2 | |
Terminated |
NCT04083170 -
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
|
Phase 2 | |
Recruiting |
NCT02464696 -
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
|
N/A | |
Withdrawn |
NCT04820894 -
Perception of Cure Among Patients With Metastatic Cancer
|
||
Completed |
NCT03125070 -
Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant
|
Phase 3 | |
Completed |
NCT01664910 -
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
|
Phase 1/Phase 2 |